Study: Slow Approval Times in EU Mean Unequal Cancer Treatment

Speedier regulatory and economic reviews of new cancer drugs are necessary for European patients to have equal access to cancer treatment, a study finds. While survival rates for most cancers are improving, disparities remain within Europe, the report says. The study authors attribute the disparities to lengthy review times, which can slow the introduction of promising new drugs.
International Pharmaceutical Regulatory Monitor